Multi-target immunotherapy for high-risk myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of immunotherapy drugs for patients with newly diagnosed, high-risk multiple myeloma. The goal is to see if this multi-target approach can improve outcomes by using the immune system to attack the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with active multiple myeloma that needs treatment, or have smoldering myeloma that has progressed.
- You must have received little or no prior myeloma treatment (less than 2 months). Bone-strengthening drugs and local radiation are okay.
- Your myeloma must have at least one 'high-risk' feature, such as certain chromosome changes, a high beta-2-microglobulin, tumors outside the bone, many lesions on a PET scan, high LDH, or myeloma cells in your blood.
- You must be between 18 and 75 years old.
- Your organs must be working well enough: adequate kidney, heart, and lung function.
- You must not have poorly controlled diabetes, high blood pressure, active infections, or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs—daratumumab plus either teclistamab or talquetamab—for people who have just been diagnosed with multiple myeloma and are considered frail. The goal is to see if this treatment is safe and effective for those who may not be strong enough for standard therapies.
This study tests a new combination of drugs for people newly diagnosed with a high-risk form of multiple myeloma. The goal is to see if this combination is safe and works better than standard treatments.
This study tests whether a combination of two new antibody drugs (teclistamab and talquetamab) works better than the standard combination (daratumumab and lenalidomide) for patients who still have minimal myeloma left after a stem cell transplant. The goal is to see if the new treatment can completely eliminate the remaining cancer cells and improve long-term outcomes.
This trial tests two immunotherapy drugs (teclistamab and daratumumab) for people with high-risk smoldering myeloma to see if the combination can stop or delay progression to active multiple myeloma. It's a new approach for those whose smoldering myeloma has a higher chance of becoming active.
This trial is testing a new combination of drugs for people with untreated multiple myeloma who are healthy enough for a stem cell transplant. It aims to see if the treatment is safe and effective.
This trial studies a precision approach to treat people with high-risk smoldering myeloma (a condition that can turn into active myeloma). The goal is to see whether the treatment can slow or prevent progression and improve outcomes.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.